Abenza announces investment in bioconjugation and ADC capabilities

Betsy Goodfellow | March 28, 2024 | News story | Business Services ADC, Abenza, Pharmacy, bioconjugation, investment 

Abenza has announced a major investment in bioconjugation and antibody drug conjugate (ADC) capabilities in response to an increasing industry demand.

The company intends to expand its bioconjugate development and cGMP manufacturing site in Bristol, Pennsylvania, US, with a $5m investment. It is hoped that the company can spend the investment on expanding its laboratory space, acquiring new equipment and upgrading its facilities, while building on the existing bioconjugation capabilities at the site.

Ian Glassford, vice president and head of the Bristol site, commented: “The integration of the Waters Arc Premier and ACQUITY Premier Chromatography systems alongside the Sartorius Hipersep Flowdrive represents a quantum leap in our operational capabilities. Combined with our comprehensive site renovations, these advancements enhance our capabilities to better support customer programmes and affirms our dedication to creating a supportive workplace for our employees.”

Matt Stober, CEO of Abzena, added: “The strategic investment into our Bristol site demonstrates our continued commitment to deliver high-quality programmes for our customers that offer them the best chances of downstream success. We have seen a significant increase in bioconjugate and antibody-drug conjugate (ADC) programmes in today’s development pipelines, and as an industry leader with over 20 years of experience in this space, we will continue to invest in our facilities across all of our sites to offer cost and time efficiencies so that these programmes can reach patients faster.”

Betsy Goodfellow

Related Content

Sanofi adds €1bn funding for biomanufacturing projects in France

Sanofi has announced that it has made a new investment of at least €1bn for …

Upperton Pharma Solutions announces £5m investment into sterile drug manufacturing

UK-based contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions has announced a £5m investment …

DelSiTech announces closing of €10m financing round for silica-based drug delivery platform

DelSiTech has announced the successful completion of a €10m financing round, marking the largest single …

Latest content